United Therapeutics Corporation
HealthcareNASDAQ:UTHR · NASDAQ Global Select
+$0.56 today
Vol 0.43M · Avg 0.54M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
18.8%
avg 19.3%
ROIC
16.1%
avg 15.8%
ROA
16.9%
avg 15.4%
Analysis
ROE is currently the strongest return metric at 18.8% versus its period average of 19.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Martine A. Rothblatt | Founder, Chairman & Chief Executive Officer | $5.84M | — | 71 | $50,410.00 | 0.12% |
Michael I. Benkowitz | President & Chief Operating Officer | $4.81M | — | 54 | $99,720.00 | 0.23% |
James C. Edgemond | Chief Financial Officer & Treasurer | $2.59M | — | 58 | $28,234.00 | 0.07% |
Paul A. Mahon | Executive Vice President, General Counsel & Corporate Secretary | $2.49M | — | 62 | $105,640.00 | 0.25% |
Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation | — | — | — | — | — |
Harrison Silvers | Manager of Investor Relations | — | — | — | — | — |
Holly Hobson | Associate Vice President of Human Resources | — | — | — | — | — |
Gil Golden | Senior Vice President & Chief Medical Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
165
$90.69M
Net Sentiment
$90.69M
Net selling
Most Active
ROTHBLATT MARTINE A
111 transactions
1–10 of 165
Analysis
Insiders reported 0 buys worth $0.00 and 165 sells worth $90.69M over the last 12 months. That adds up to net selling of $90.69M. ROTHBLATT MARTINE A was the most active insider with 111 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +30.6% | +10.8% (15yr)4 analysts |
| Revenue | N/A | N/A | +17.0% | +10.1% (15yr)5 analysts |
| Net Income | N/A | N/A | +28.9% | +10.3% (15yr)5 analysts |
| EBIT | N/A | N/A | +18.4% | +12.5% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EPS at +30.6% over three years. Forward estimates point to EBIT at +12.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.53B
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Incyte Corporation
NASDAQ:INCY
$21.68B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
Who manages UTHR?
United Therapeutics Corporation (UTHR) lists 8 active executives. The top listed executive is Paul A. Mahon, Executive Vice President, General Counsel & Corporate Secretary.
Are UTHR insiders buying or selling?
Recent insider activity shows net selling of $91.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.